+

WO2013100251A1 - Méthodes de criblage d'agents anticancéreux par l'examen de l'étendue de la méthylation de la pontine - Google Patents

Méthodes de criblage d'agents anticancéreux par l'examen de l'étendue de la méthylation de la pontine Download PDF

Info

Publication number
WO2013100251A1
WO2013100251A1 PCT/KR2012/000937 KR2012000937W WO2013100251A1 WO 2013100251 A1 WO2013100251 A1 WO 2013100251A1 KR 2012000937 W KR2012000937 W KR 2012000937W WO 2013100251 A1 WO2013100251 A1 WO 2013100251A1
Authority
WO
WIPO (PCT)
Prior art keywords
pontin
cells
methylation
hypoxia
hif
Prior art date
Application number
PCT/KR2012/000937
Other languages
English (en)
Inventor
Sung-Hee Baek
Jason S. LEE
Yunho Kim
Original Assignee
Seoul National University R&Db Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University R&Db Foundation filed Critical Seoul National University R&Db Foundation
Publication of WO2013100251A1 publication Critical patent/WO2013100251A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Definitions

  • hypoxia and Pontin expression can synergistically act on hypoxia responsive genes.
  • cluster 3 we examined cluster 3 to determine which transcription factor targets are enriched. Upon searching for genes that are affected by transcription factors that have been previously reported to modulate transcription upon hypoxic stress such as HIF-1, NF- ⁇ B and TCF/LEF (25), HIF-1 scored the highest in terms of the number of its target genes enriched in Pontin-dependent cluster 3 (from both 6 and 9 hours of hypoxia) (Fig. 3G).
  • Kastan MB et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71(4):587-597.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de criblage d'un agent anticancéreux par la mesure du taux de méthylation de la Pontine. Le procédé comprend les étapes consistant à : cultiver des cellules ; mettre en contact une substance potentielle avec les cellules ; déterminer si le taux de méthylation de la Pontine dans les cellules diminue par rapport à celui dans les cellules témoins (qui n'ont pas été mises en contact avec la substance potentielle) ; et sélectionner la substance potentielle en tant qu'agent anticancéreux si le taux de méthylation de la Pontine dans les cellules diminue.
PCT/KR2012/000937 2011-12-31 2012-02-08 Méthodes de criblage d'agents anticancéreux par l'examen de l'étendue de la méthylation de la pontine WO2013100251A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0148029 2011-12-31
KR1020110148029A KR101849409B1 (ko) 2011-12-31 2011-12-31 폰틴의 메틸화 정도를 이용한 항암제 스크리닝 방법

Publications (1)

Publication Number Publication Date
WO2013100251A1 true WO2013100251A1 (fr) 2013-07-04

Family

ID=48697699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000937 WO2013100251A1 (fr) 2011-12-31 2012-02-08 Méthodes de criblage d'agents anticancéreux par l'examen de l'étendue de la méthylation de la pontine

Country Status (2)

Country Link
KR (1) KR101849409B1 (fr)
WO (1) WO2013100251A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585909A4 (fr) * 2017-02-23 2020-12-23 The Council of the Queensland Institute of Medical Research Biomarqueurs pour le diagnostic d'affections

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102323335B1 (ko) * 2020-11-25 2021-11-05 서울대학교산학협력단 Carm1에 의한 pontin의 아르기닌 메틸화를 통한 자가포식 조절 방법 및 그 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104500A1 (en) * 2000-05-12 2003-06-05 Gstaiger Matthias Georg Christian Enzymatic assays for screening anti-cancer agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090012385A1 (en) 2004-10-13 2009-01-08 Masahiro Takizawa Magnetic Resonance Imaging Device and Method
KR100986345B1 (ko) 2007-11-26 2010-10-08 재단법인서울대학교산학협력재단 폰틴의 수모화를 이용한 항암제 스크리닝 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104500A1 (en) * 2000-05-12 2003-06-05 Gstaiger Matthias Georg Christian Enzymatic assays for screening anti-cancer agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRIGOLETTO, A. ET AL.: "The multifaceted proteins reptin and pontin as major players in cancer.", BIOCHIM. BIOPHY. ACTA, vol. 1815, April 2011 (2011-04-01), pages 147 - 157 *
LEE, J. S. ET AL.: "Hypoxia-induced methylation of a pontin chromatin remodeling factor.", P.N.A.S, vol. 108, no. 33, 16 August 2011 (2011-08-16), pages 13510 - 13515 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585909A4 (fr) * 2017-02-23 2020-12-23 The Council of the Queensland Institute of Medical Research Biomarqueurs pour le diagnostic d'affections

Also Published As

Publication number Publication date
KR20130078865A (ko) 2013-07-10
KR101849409B1 (ko) 2018-06-01

Similar Documents

Publication Publication Date Title
Basu et al. Epigenetic mechanisms underlying maternal diabetes-associated risk of congenital heart disease
Ortmann et al. The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes
Ren et al. MCU-dependent mitochondrial Ca2+ inhibits NAD+/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells
Pekovic-Vaughan et al. The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis
Chen et al. CTNNB1/β-catenin dysfunction contributes to adiposity by regulating the cross-talk of mature adipocytes and preadipocytes
Suzuki et al. Regulation of hypoxia-inducible gene expression after HIF activation
Nascimento et al. The opposing transcriptional functions of Sin3a and c-Myc are required to maintain tissue homeostasis
Bonora et al. Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction
Zhou et al. p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild‐type p53
Zhang et al. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis
Liu et al. Long noncoding RNA LINC00518 induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1α negative feedback loop in melanoma
Wang et al. KRAB-type zinc-finger proteins PITA and PISA specifically regulate p53-dependent glycolysis and mitochondrial respiration
Tajima et al. Ca2+‐activated K+ channels in human melanoma cells are up‐regulated by hypoxia involving hypoxia‐inducible factor‐1α and the von Hippel‐Lindau protein
Lima et al. Essential role of the PGC‐1α/PPARβ axis in Ucp3 gene induction
Kim et al. Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1
Yao et al. CHD7 represses the retinoic acid synthesis enzyme ALDH1A3 during inner ear development
Matsumoto et al. Genomewide approaches for BACH 1 target genes in mouse embryonic fibroblasts showed BACH 1‐Pparg pathway in adipogenesis
JP2017520774A (ja) Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝
Tsou et al. Genome‐wide reduction in chromatin accessibility and unique transcription factor footprints in endothelial cells and fibroblasts in scleroderma skin
Zhi et al. PRMT3 regulates the progression of invasive micropapillary carcinoma of the breast
Gao et al. The role of stem cell factor SALL4 in leukemogenesis
Cui et al. Cooperation between IRTKS and deubiquitinase OTUD4 enhances the SETDB1-mediated H3K9 trimethylation that promotes tumor metastasis via suppressing E-cadherin expression
Zhu et al. Methylation status of CpG sites in the NOTCH4 promoter region regulates NOTCH4 expression in patients with tetralogy of Fallot
WO2013100251A1 (fr) Méthodes de criblage d'agents anticancéreux par l'examen de l'étendue de la méthylation de la pontine
Han et al. Loss of GLTSCR1 causes congenital heart defects by regulating NPPA transcription

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12861119

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12861119

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载